Findings of a randomized and controlled trial conducted by researchers from New Mexico Clinical Research & Osteoporosis Center in Albuquerque suggest that once-monthly oral ibandronate for a year can improve spine and hip bone mineral density in postmenopausal women in the age group of 55 to 80 years. To measure the strength, quantitative computed tomography (QCT) and dual-energy x-ray absorptiometry (DXA) were used. The study was supported by Roche and GlaxoSmithKline.